Get on top of gout with a fresh look at treatment options
AbstractManaging increasingly prevalent gout, which stems from hyperuricaemia, is not easy. Flare management and long-term serum urate-lowering (ULT) therapy, largely with xanthine oxidase inhibitors (XOIs) or uric acid transporter 1 inhibitors (URAT1Is), are core strategies, but robust comparative trials in these agents are limited. Several are associated, sometimes undeservedly, with adverse drug events. Pipeline URAT1Is report 60 –70% decreases in serum urate, to< 5 mg/dL in most patients. These URAT1Is, plus new XOIs, combination regimens, immunosuppressant adjuncts for intravenous uricases and uricosuric comorb...
Source: Drugs and Therapy Perspectives - April 4, 2024 Category: Drugs & Pharmacology Source Type: research
Sparsentan in immunoglobulin A nephropathy: a profile of its use
AbstractSparsentan (FILSPARI®), an oral, dual endothelin and angiotensin receptor antagonist, is an emerging new treatment option for patients with immunoglobulin A (IgA) nephropathy. Sparsentan received accelerated approval in the USA for the treatment of adults with IgA nephropathy who are at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UP/C) ≥ 1.5 g/g, as well as a positive opinion recommending approval in the EU. In the ongoing phase 3 PROTECT trial in adults with IgA nephropathy, sparsentan was associated with favourable antiproteinuric effects, which were maintained over 110 ...
Source: Drugs and Therapy Perspectives - March 29, 2024 Category: Drugs & Pharmacology Source Type: research
What is the role of pioglitazone for patients with type 2 diabetes in value-based care settings?
This article discusses advantages and disadvantages of pioglitazone therapy, selecting patients who may be candidates for pioglitazone therapy, and considerations for prescribing in value-based settings. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - March 28, 2024 Category: Drugs & Pharmacology Source Type: research
Treating paediatric Crohn ’s disease is challenging but new treatments hold promise
This article reviews the efficacy and safety of these drugs, as well as common clinical challenges encountered in treating paediatric patients with this condition. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - March 28, 2024 Category: Drugs & Pharmacology Source Type: research
Be aware of the risks of nephrotoxicity when prescribing amoxicillin and third-generation cephalosporins
AbstractAmoxicillin and third-generation cephalosporins are widely used in the prevention and treatment of established infections. These broad-spectrum antibiotics are mainly excreted via urine and are considered relatively safe. However, several reports have indicated that substantial nephrotoxicity (e.g. acute interstitial nephritis and crystal nephropathy) occurs with amoxicillin and several cases of nephrotoxicity have been reported with ceftriaxone. While corticosteroids have been shown to improve kidney function in some patients with acute interstitial nephritis, close monitoring of kidney function for acute kidney i...
Source: Drugs and Therapy Perspectives - March 21, 2024 Category: Drugs & Pharmacology Source Type: research
Correction to: Nadofaragene firadenovec in high-risk Bacillus Calmette Gu érin unresponsive non-muscle invasive bladder cancer: a profile of its use
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - March 21, 2024 Category: Drugs & Pharmacology Source Type: research
Correction to: Efanesoctocog alfa in hemophilia A: a profile of its use
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - March 21, 2024 Category: Drugs & Pharmacology Source Type: research
Buprenorphine extended-release injection (Brixadi ®) in the management of opioid use disorder: a profile of its use in the USA
AbstractBuprenorphine extended-release (ER) injection for subcutaneous use (Brixadi®; CAM2038; hereafter referred to as buprenorphine ER) is a useful addition to the treatment options for opioid use disorder (OUD). Brixadi® is formulated using FluidCrystal® injection depot technology, allowing for a low volume prefilled syringe and steady release of buprenorphine over one week or one month. In a pivotal phase 3 trial, weekly or monthly subcutaneous buprenorphine ER was non-inferior to daily sublingual buprenorphine/naloxone in terms of the proportion of opioid-negative urine samples and the responder rate. Based on th...
Source: Drugs and Therapy Perspectives - March 15, 2024 Category: Drugs & Pharmacology Source Type: research
Treat bipolar depression with atypical antipsychotics and mood stabilisers; new therapies require further study
AbstractPatients with bipolar disorder frequently suffer from episodes of depression, which is a major cause of morbidity. A range of atypical antipsychotics and mood stabilisers are recommended in guidelines for the treatment of bipolar depression but there is no consensus on which therapies should be used in the first line. Many patients remain symptomatic and experience relapse despite treatment. Pharmacotherapies with efficacy in other depressive disorders and those with novel mechanisms of action (including those targeting neuronal plasticity, inflammation, mitochondrial function) are currently being investigated for ...
Source: Drugs and Therapy Perspectives - March 11, 2024 Category: Drugs & Pharmacology Source Type: research
Metformin reduces the complications of gestational diabetes mellitus but its long-term effects on offspring require further study
AbstractGestational diabetes mellitus (GDM) can lead to serious complication during pregnancy both for the pregnant person and the developing offspring. Intensive lifestyle intervention, including diet and exercise, is effective in managing this disorder, although pharmacotherapy (typically insulin) will still be required in approximately a quarter of these patients. Recent studies have shown that metformin can also be efficacious in reducing complications associated with GDM, however, longer-term safety data in offspring are still required. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - March 10, 2024 Category: Drugs & Pharmacology Source Type: research
Multisite primary care led amoxicillin challenge pathway to safely remove penicillin allergy label
ConclusionsOur study demonstrates a pediatric specific screener and pathway for pediatric providers to safely remove penicillin allergy labels following latest allergy practice parameters. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - March 10, 2024 Category: Drugs & Pharmacology Source Type: research
Administer antidepressants during pregnancy on a case-by-case basis
AbstractAntidepressants are often avoided during pregnancy due to the concern that they may cause harm to the developing foetus. Observational studies, the results of which are notoriously subject to confounds and biases, have demonstrated prenatal antidepressant exposure to be associated with a range of adverse outcomes. Many risk estimates are likely to have been inflated, although some associations do remain in adequately controlled analyses. Clinicians should provide pregnant patients with up-to-date information on risks based on the strongest evidence available. The possible risks of antidepressants need to be careful...
Source: Drugs and Therapy Perspectives - March 10, 2024 Category: Drugs & Pharmacology Source Type: research
Mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancers: a profile of its use
AbstractMirvetuximab soravtansine (ElahereTM), an antibody-drug conjugate carrying a maytansinoid payload targeting folate receptor alpha (FR α), is a valuable new treatment option for patients with FRα-positive, platinum-resistant ovarian cancer. Mirvetuximab soravtansine significantly improved objective response rates compared with historical rates in patients with FRα-positive, platinum-resistant ovarian cancer in the phase 2 SORAYA trial. In the confirmatory phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved median progression-free survival, objective response rates, and median overall survival ...
Source: Drugs and Therapy Perspectives - March 10, 2024 Category: Drugs & Pharmacology Source Type: research
Platelet-rich plasma therapy for chronic cutaneous wounds stratified by etiology: a systematic review of randomized clinical trials
ConclusionsPRP may improve the healing of venous ulcers; however, there is no strong evidence regarding this positive effect in other wound etiologies. Although autologous PRP therapy is widely used, its effectiveness according to wound etiology is still not clear. The heterogenicity of the protocols to prepare and apply PRP therapy and the different methods for measuring chronic wound outcomes hinder the comparison of studies, thereby limiting the possibility of conducting a more robust analysis.The systematic review was prospectively registered with PROSPERO under number CRD42021251501. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - February 28, 2024 Category: Drugs & Pharmacology Source Type: research
Nadofaragene firadenovec in high-risk Bacillus Calmette Gu érin unresponsive non-muscle invasive bladder cancer: a profile of its use
AbstractNadofaragene firadenovec (Adstiladrin®) is an important bladder-sparing option in the treatment of patients with high-risk Bacillus Calmette Gu érin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). Radical cystectomy is the recommended treatment in these patients; however, many are ineligible or refuse to undergo this major procedure and other options are limited. Intravesical nadofaragene firadenovec, a replication-deficient adenovirus-based gene therapy that causes localized expression of interferon (IFN) α2b in the bladder, is approved in the USA for the treatment of adults with high-risk BCG-un...
Source: Drugs and Therapy Perspectives - February 24, 2024 Category: Drugs & Pharmacology Source Type: research
